期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

低分化甲状腺癌临床病理学进展 被引量：8

原文传递
导出
摘要 低分化甲状腺癌（poorly differentiated thyroid carcinoma,PDTC）概念的提出已超过25年,用来描述在临床病理特点上介于分化型癌（滤泡癌和乳头状癌）与未分化型癌（间变性癌）之间的一种甲状腺滤泡源性肿瘤.PDTC曾被冠以多种名称,如低分化滤泡癌、实性型滤泡癌[1]、低分化乳头状癌、梁状癌[2]及岛状癌[3]等.虽然20多年的研究均支持存在这样一种类型的甲状腺癌,但对其具体定义学者们并未达成一致.近年来,有关PDTC的研究报道逐渐增多,已成为临床医师及病理医师关注的热点之一.一、PDTC的定义从PDTC的概念提出伊始,就存在对此种肿瘤各种不同的具体定义.1983年,Sakamoto等[4]学者基于日本的研究经验,将具有实性、梁状或硬化结构的甲状腺滤泡癌或乳头状癌定义为PDTC（不论其是否存在高级别的细胞特点如核分裂象较多及坏死）.1984年,Carcangiu等[5]将具有岛状生长方式,出现坏死及较多核分裂象的甲状腺滤泡源性肿瘤定义为PDTC.自此以后,文献中对于PDTC的解释就变得十分多样.其中日本学者普遍采用Sakamoto的定义[6],而欧美学者遵从Carcangiu定义的较多[3].此外,尚有学者将此两种定义综合后使用,或者将PDTC的定义扩展到包括甲状腺黏液表皮样癌及柱状细胞癌的范畴[1].
作者 孙健 杨堤 崔全才
机构地区 中国医学科学院北京协和医学院北京协和医院病理科
出处 《中华病理学杂志》 CAS CSCD 北大核心 2011年第12期850-853,共4页 Chinese Journal of Pathology
关键词 低分化滤泡癌 甲状腺癌 临床病理学 carcinoma 甲状腺滤泡癌 PDTC 乳头状癌 临床病理特点
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1Sobrinho-Simoes M,Sambade C,Fonseca E,et al.Poorly differentiated carcinomas of the thyroid gland:a review of the clinicopathologic features of a series of 28 cases of a heterogeneous,clinically aggressive group of thyroid tumors.Int J Surg Pathol,2002,10(2):123-131.
  • 2Cabanne F,Gerard-Marchant R,Heimann R,et al.Malignant tumors of the thyroid gland.Problems of histopathologic diagnosis.Apropos of 692 lesions collected by the thyroid cancer Cooperative Group of the O.E.R.T.C.Ann Anat Pathol (Paris),1974,19(2):129-148.
  • 3Pilotti S,Collini P,Mariani L,et al.Insular carcinoma:a distinct de novo entity among follicular carcinomas of the thyroid gland.Am J Surg Pathol,1997,21 (12):1466-1473.
  • 4Sakamoto A,Kasai N,Sugano H.Poorly differentiated carcinoma of the thyroid.A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas.Cancer,1983,52 (10):1849-1855.
  • 5Carcangiu ML,Zampi G,Rosai J. Poorly differentiated (“ insular”) thyroid carcinoma.A reinterpretation of Langhans’“wuchernde Struma”.Am J Surg Pathol,1984,8 (9):655-668.
  • 6Nishida T,Katayama S,Tsujimoto M,et al.Clinicopathological significance of poorly differentiated thyroid carcinoma.Am J Surg Pathol,1999,23(2):205-211.
  • 7DeLellis RA,LLoyd R,Heitz PU.WHO classification of tumours.Pathology and genetics-tumorus of endocrine organs.Lyon:IARC Press,2004.
  • 8Volante M,Collini P,Nikiforov YE,et al.Poorly differentiated thyroid carcinoma:the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach.Am J Surg Pathol,2007,31 (8):1256-1264.
  • 9Asioli S,Erickson LA,Righi A,et al.Poorly differentiated carcinoma of the thyroid:validation of the Turin proposal and analysis of IMP3 expression.Mod Pathol,2010,23 (9):1269-1278.
  • 10Ito Y,Hirokawa M,Fukushima M,et al.Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan.World J Surg,2008,32 (7):1535-1543.

二级参考文献11

  • 1Kawachi K, MatsushitaY,Yonezawa S,et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol,2000,31: 428-433.
  • 2Cvejic D,Savin S, Golubovic S,et al.Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression. Histopathology, 2000, 37: 530-535.
  • 3Beesley MF, Mclaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules.Histopathology,2002,41:236-243.
  • 4RenshawAA,Gould EW. Why there is the tendency to ''overdiangnose'' the follicular variant of papillary thyroid carcinoma. Am J Clin Pathol, 2002,117:19-21.
  • 5Miettinen M,Kovatich AJ,Karkkainen P. Keratin subsets in papillary and follicular thyroid lesions:A paraffin section analysis with diagnosis implications.Vichows Arch,1997,431:407-413.
  • 6Baloch ZW,Abraham S,Roberts S,et al. Differential expression of cytokeratins in follicular variant papillary carcinoma:an imunohistochemical study and its diagnostic utility. Hum Pathol,1999,30:1166-1171.
  • 7Inohara H,Honjo Y,Yoshii T,et al. Expression of galectin-3 in fine-needle aspirates as a marker differentiating benign from malginant thyroid neoplasms. Cancer,1999,85:2475-2481.
  • 8Coli A,Bigotti G,Zucchetti F,et al.Galectin-3,a marker of well-differentiated thyroid carcinoma,is expressed in thyroid nodules with cytological atypia.Histopathology,2002,40:80-87.
  • 9van Hoeven KH, Kovatich AJ, Miettinen M. Immunocytochemical evaluation of HBME-1, CA 19-9, and CD-15 (Leu-M1) in fine-needle aspirates of thyroid nodules. Diagn Cytopathol, 1998,18: 93-97 .
  • 10Hirokawa M, Horiguchi H,Wakatsuki S,et al.Intranodal benign thyroid tissue: significance of HBME-1 in differentiation from metastatic papillary thyroid carcinoma. APMIS,2001,109: 875-880.

共引文献32

同被引文献38

引证文献8

二级引证文献21

中华病理学杂志
2011年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部